Acquired platelet antagonism: off‐target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors
Author(s): ,
B. M. E. Tullemans
Affiliations:
Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, the Netherlands
,
J. W. M. Heemskerk
Affiliations:
Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, the Netherlands
M. J. E. Kuijpers
Affiliations:
Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, the Netherlands
Correspondence: Marijke J. E. Kuijpers, Department of Biochemistry (CARIM), Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands|Tel.: +31 43 388 1537|E‐mail: Marijke.Kuijpers@maastrichtuniversity.nl
ISTH Academy. Kuijpers M. Sep 4, 2018; 230961
Marijke Kuijpers
Marijke Kuijpers

Access to Premium content is currently a membership benefit.


Click here to join ISTH or renew your membership.

Journal Abstract
Discussion Forum (0)
Rate & Comment (0)




Keyword(s)
cancer, platelets, signaling, therapy, tyrosine kinase inhibitor
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies